Local News

• Abbott recognized on Dow Jones Sustainability Index (DJSI) for fourth consecutive year  Abbott announced that it was recognized on the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the fourth consecutive year.
  Abbott September 04, 2008  
• Amgen and Wyeth statement on the FDA Safety Announcement regarding TNF blockers  Amgen and Wyeth Pharmaceuticals issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers (marketed as Remicade(R), Enbrel(R), Humira(R) and Cimzia(R)).
  Amgen September 04, 2008  
• Percutaneous coronary intervention with CYPHER(R) stent comparable to bypass surgery  Data from the largest randomized trial of its kind performed to date indicate that the use of percutaneous coronary intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent was comparable to bypass surgery in key safety endpoints in patients with multi-vessel disease and diabetes.
  Johnson & Johnson September 04, 2008  
• Monsanto's Roundup Ready 2 Yield(TM) Soybeans receive China regulatory approval  Monsanto Company announced it has received regulatory approval in China for the importation of Roundup Ready 2 Yield(TM) soybeans. China imports accounted for approximately 38 percent of U.S. soybean exports in 2007, making it the largest purchaser of U.S. soybeans.
  Monsanto Company September 04, 2008  
• Azaya licenses Health Science Center technology to treat cancer  Azaya Therapeutics has licensed a technology that could be beneficial in treating head and neck cancers, the company said. The technology involves the use of liposomes to deliver radiation into the head and neck tumors through a direct injection.
  San Antonio Business Journal September 03, 2008  
• Opexa Therapeutics and Myelin Repair Foundation partner on MS research program  Opexa Therapeutics announced the establishment of a novel MS research partnership with the Myelin Repair Foundation (MRF). Opexa and the MRF will work to identify therapeutically relevant biomarkers in MS that may provide important insight to support the continued development of Tovaxin(R).
  Opexa Therapeutics September 03, 2008  
• ViroPharma and Lev receive Hart-Scott-Rodino Clearance from FTC  ViroPharma and Lev Pharmaceuticals announced that the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act has expired in connection with ViroPharma's proposed acquisition of Lev Pharmaceuticals.
  ViroPharma Inc. September 03, 2008  
• Pfizer and Medivation enter into global agreement to co-develop and market Dimebon  Pfizer and Medivation have entered into an agreement to develop and commercialize Dimebon, Medivation's investigational drug for Alzheimer's disease and Huntington's disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial.
  Pfizer Inc September 03, 2008  
• Gates Foundation accepting proposals for Grand Challenges Explorations Round 2  The Bill & Melinda Gates Foundation announced that it is now accepting grant proposals for Round 2 of Grand Challenges Explorations, a five-year US$100 million initiative to encourage bold and unconventional research on new global health solutions. Proposals will be accepted through November 2.
  The Bill & Melinda Gates Foundation September 03, 2008  
• Wyeth names Daniel J. McIntyre vice president, corporate communications  Wyeth announced the appointment of Daniel McIntyre to VP, Corporate Communications. Mr. McIntyre will be responsible for all internal and external communications for the corporation and its three major divisions -- pharmaceuticals, consumer health care and animal health -- around the world.
  Wyeth September 03, 2008  

   (next 10 articles)